BIOMERICA INC BMRA
Nasdaq · XNAS · stock · In Vitro & In Vivo Diagnostic Substances
Chart by TradingView
2/9
Piotroski F — financial health
-29.16
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $5.3M | -$5.0M | $498,000 | — | $4.1M |
| 2024 | $5.4M | -$6.0M | $611,000 | -$5.4M | $6.6M |
| 2023 | $5.3M | -$7.1M | $446,000 | -$5.5M | $11.7M |
| 2022 | $18.9M | -$4.5M | $3.0M | -$536,000 | $8.3M |
| 2021 | $7.2M | -$7.4M | $366,285 | -$5.4M | $9.2M |
| 2020 | $6.7M | -$2.3M | $1.8M | -$4.3M | $14.2M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Chin Eric | director | 2025-12-12 | Grant | 22,500 | — |
| Lu Gary | Chief Financial Officer | 2025-12-12 | Grant | 40,000 | — |
| Irani Zackary S. | Chief Executive Officer | 2025-12-12 | Grant | 52,500 | — |
| BARBIERI ALLEN | Executive Vice-Chairman | 2025-12-12 | Grant | 30,000 | — |
| MOATAZEDI DAVID | director | 2025-12-12 | Grant | 20,000 | — |
| Gary M. Huff | director | 2025-12-12 | Grant | 20,000 | — |
| Emerson Jane | director | 2024-12-13 | Grant | 85,000 | $0.31 |
| Irani Zackary S. | Chief Executive Officer | 2024-12-13 | Grant | 250,000 | $0.31 |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -29.16 (distress)
- Working capital / assets 0.527
- Retained earnings / assets -8.943
- EBIT / assets -0.864
- Equity / liabilities 2.231
Source: SEC EDGAR filings · CIK 0000073290 · as of 2025-05-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.